Qian Yang

Prof. Dr. Qian Yang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2015 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LFLi Fan
Li Fan
QYQian Yang
Qian Yang
JTJiali Tan
Jiali Tan
YQYoubei Qiao
Youbei Qiao
QWQiaofeng Wang
Qiaofeng Wang
YZYongsheng Zhang
Yongsheng Zhang
Background: Dual loading drug delivery system with tumor targeting efficacy and sequential release function provides a promising platform for anticancer drug delivery. Herein, we established a novel AuCOOH@FACS nanogel system for co-delivery miR-218 mimics (as bio-drug) and Temozolomide(as chemo-drug). Methods: DLS and TEM were employed to determine the characteristics of particles and nanogels. The cell viability was calculated for study synergistic effect of both drugs coadministration and in nanogel forms. The amounts of Au uptake were measured by ICP-MS in cell and tumors to quantify the targeting drug delivery efficacy. Tumor weight and mice weight were investigated to study the targeting antitumor efficacy of nanogel system. Results: The results revealed that using AuCOOH@FACS nanogel as delivery vehicles, drugs could be targeting delivery to tumor site, the intracellular uptake is enhanced to a greater extent, and significant antitumor efficacy is fold increase compared with free drug administration group, without noticeable system cytotoxicity. Conclusions: This system offers an efficient approach to cancer therapy and holds significant potential to improve the treatment of cancer in the future.

9 November 2017 in Discover Nano
Verified
Journal Article
Open access
PDF file
JYJiani Yuan
Jiani Yuan
XZXuanxuan Zhou
Xuanxuan Zhou
WCWei Cao
Wei Cao
LBLinlin Bi
Linlin Bi
YZYifang Zhang
Yifang Zhang
WSWang Siwang
Wang Siwang
Bufalin was reported to show strong pharmacological effects including cardiotonic, antiviral, immune-regulation, and especially antitumor effects. The objective of this study was to determine the characterization, antitumor efficacy, and pharmacokinetics of bufalin-loaded PEGylated liposomes compared with bufalin entity, which were prepared by FDA-approved pharmaceutical excipients. Bufalin-loaded PEGylated liposomes and bufalin-loaded liposomes were prepared reproducibly with homogeneous particle size by the combination of thin film evaporation method and high-pressure homogenization method. Their mean particle sizes were 127.6 and 155.0 nm, mean zeta potentials were 2.24 and − 18.5 mV, and entrapment efficiencies were 76.31 and 78.40%, respectively. In vitro release profile revealed that the release of bufalin in bufalin-loaded PEGylated liposomes was slower than that in bufalin-loaded liposomes. The cytotoxicity of blank liposomes has been found within acceptable range, whereas bufalin-loaded PEGylated liposomes showed enhanced cytotoxicity to U251 cells compared with bufalin entity. In vivo pharmacokinetics indicated that bufalin-loaded PEGylated liposomes could extend or eliminate the half-life time of bufalin in plasma in rats. The results suggested that bufalin-loaded PEGylated liposomes improved the solubility and increased the drug concentration in plasma.

1 March 2024 in International Journal of Minerals, Metallurgy and Materials
Verified
Journal Article
Closed access
PDF file
YTYi Tian
Yi Tian
ZFZhiguang Fu
Zhiguang Fu
XZXiaosheng Zhu
Xiaosheng Zhu
CZChunjing Zhan
Chunjing Zhan
JHJinwei Hu
Jinwei Hu
MSMei Shi
Mei Shi